Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 7:34 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1873–1896 of 5,931 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Mouth Disease Clear all

Conditions: Advanced Solid Tumor
Interventions: CLR457; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 3
States / cities: Boston, Massachusetts • New York, New York • Nashville, Tennessee

Conditions: Plaque, Gingivitis
Interventions: stannous fluoride toothpaste, cavity protection toothpaste; Drug
Lead sponsor: Procter and Gamble; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Fort Wayne, Indiana

Conditions: Diabetes Mellitus, Type 1
Interventions: Empagliflozin, Placebo; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 730 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 34
States / cities: Escondido, California • Huntington Beach, California • Los Angeles, California + 31 more

Conditions: Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis
Interventions: Momelotinib; Drug
Lead sponsor: Sierra Oncology LLC - a GSK company; Industry
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 3
States / cities: Stanford, California • Boston, Massachusetts • Rochester, Minnesota

Conditions: Gout
Interventions: Febuxostat, Allopurinol; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 2,269 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 258
States / cities: Birmingham, Alabama • Hoover, Alabama • Hueytown, Alabama + 255 more

Conditions: Dental Plaque
Interventions: Manual Toothbrush, Interproximal Cleaning Device; Device
Lead sponsor: Philips Oral Healthcare; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 170 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 1
States / cities: Fort Wayne, Indiana

Conditions: Leukemia
Interventions: cyclophosphamide, cytarabine, daunorubicin hydrochloride, dexamethasone, doxorubicin hydrochloride, mercaptopurine, methotrexate, pegaspargase, thioguanine, vincristine sulfate, radiation therapy; Drug · Radiation
Lead sponsor: Children's Oncology Group; Network
Eligibility: 1 Year to 9 Years
Enrollment: 3,054 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2008
U.S. locations: 116
States / cities: Phoenix, Arizona • Downey, California • Duarte, California + 92 more

Conditions: Gingivitis, Investigation of Biological Markers of Inflammation
Interventions: Iocide Oral Rinse, Placebo; Drug
Lead sponsor: Biomedical Development Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome, Hematologic Malignancies
Interventions: AG881; Drug
Lead sponsor: Agios Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 5
States / cities: Aurora, Colorado • Chicago, Illinois • Boston, Massachusetts + 2 more

Conditions: Bipolar Disorder, Schizophrenia
Interventions: Seroquel IR 300mg, Seroquel IR 25mg, Quetiapine Formulation A 300mg, Quetiapine Formulation B 300mg, Quetiapine Formulation 25mg; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 1
States / cities: Long Beach, California

Conditions: Dry Mouth
Interventions: Marketed Dry Mouth Rinse, Water control, Experimental Dry Mouth Rinse; Device · Other
Lead sponsor: Procter and Gamble; Industry
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Mason, Ohio

Conditions: Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Localized Breast Carcinoma, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Triple-Negative Breast Carcinoma, Metastatic Breast Cancer
Interventions: Best Practice, Informational Intervention, Medical Device Usage and Evaluation, Quality-of-Life Assessment, Survey Administration; Other
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 4
States / cities: Atlanta, Georgia

Conditions: Contrast Induced Nephropathy
Interventions: Oral hydration, Oral sodium bicarbonate, Intravenous Hydration, Intravenous sodium bicarbonate; Other · Drug
Lead sponsor: The Western Pennsylvania Hospital; Other
Eligibility: 18 Years to 100 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2010
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Major Depressive Disorder
Interventions: CX157, Placebo; Drug · Other
Lead sponsor: CeNeRx BioPharma Inc.; Industry
Eligibility: 18 Years to 50 Years · Male only
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: Miramar, Florida

Conditions: Cancer, Physical Activity, Cancer Survivorship, Mental Health, Obesity
Interventions: AYA Connect intervention, Positive Psychology (PP) intervention, Positive Psychology Plus (PP+) intervention; Behavioral
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 18 Years to 39 Years
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Schizophrenia
Interventions: TV-44749, Oral olanzapine; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D LLC; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 153 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 6
States / cities: Los Alamitos, California • Torrance, California • Hollywood, Florida + 3 more

Conditions: Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Monoblastic Leukemia (M5a), Adult Acute Monocytic Leukemia (M5b), Adult Acute Myeloblastic Leukemia With Maturation (M2), Adult Acute Myeloblastic Leukemia Without Maturation (M1), Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Adult Acute Myelomonocytic Leukemia (M4), Adult Erythroleukemia (M6a), Adult Pure Erythroid Leukemia (M6b), Chronic Myelomonocytic Leukemia, de Novo Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Previously Treated Myelodysplastic Syndromes, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Acute Myeloid Leukemia, Refractory Anemia, Refractory Anemia With Excess Blasts, Refractory Anemia With Ringed Sideroblasts, Refractory Cytopenia With Multilineage Dysplasia, Secondary Acute Myeloid Leukemia, Secondary Myelodysplastic Syndromes, Untreated Adult Acute Lymphoblastic Leukemia, Untreated Adult Acute Myeloid Leukemia
Interventions: entinostat, sargramostim; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Tobacco Use Disorder, Oral Nicotine Pouch Use, Smoking Behaviors, Harm Reduction, Toxic Effect of Tobacco and Nicotine, Carcinogenesis
Interventions: ZYN; Device
Lead sponsor: Yale University; Other
Eligibility: 21 Years to 77 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Hypertension, Pulmonary, Pulmonary Arterial Hypertension
Interventions: Treprostinil diethanolamine, Esomeprazole; Drug
Lead sponsor: United Therapeutics; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Healthy Volunteers
Interventions: Formulation A, Formulation B, Formulation C; Drug
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years to 65 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2027
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Alcohol Use Disorder, Alcohol Dependence
Interventions: Not listed
Lead sponsor: National Institutes of Health Clinical Center (CC); NIH
Eligibility: 18 Years to 100 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Sjogren's Syndrome
Interventions: Etanercept; Drug
Lead sponsor: National Institute of Dental and Craniofacial Research (NIDCR); NIH
Eligibility: Not listed
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2003
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Rectal Neoplasms
Interventions: topotecan, radiation, surgery; Drug · Procedure
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2008
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Intestinal Disorders, Bowel Diseases, Inflammatory
Interventions: TD-1473 oral capsule, [14C]-TD-1473 IV bolus, [14C]-TD-1473 Oral Capsule; Drug
Lead sponsor: Theravance Biopharma; Industry
Eligibility: 19 Years to 55 Years · Male only
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Lincoln, Nebraska

Search by objective public record fields.

Study of CLR457 Administered Orally in Adult Patients With Advanced Solid Malignancies

A Pilot Study to Evaluate a Method for Plaque When Comparing Stannous Fluoride Toothpaste to a Regular Dentifrice

Empagliflozin as Adjunctive to InSulin thErapy Over 52 Weeks in Patients With Type 1 Diabetes Mellitus (EASE-2)

Extension Study Evaluating the Long Term Safety and Efficacy Study of CYT387 in Primary Myelofibrosis (PMF) or Post-polycythemia Vera (PV) or Post-essential Thrombocythemia (ET)

Efficacy and Safety of Oral Febuxostat in Participants With Gout

Evaluating the Effect of Tooth Cleaning Devices on Oral Health

Comparison of Different Combination Chemotherapy Regimens in Treating Children With Acute Lymphoblastic Leukemia

Efficacy of Iocide Oral Rinse Against Gingival Inflammation

Study of Orally Administered AG-881 in Patients With Advanced Hematologic Malignancies With an IDH1 and/or IDH2 Mutation

Trial to Assess the Bioavailability of Quetiapine Versus Seroquel® in Subjects With Schizophrenia or Bipolar Disorder

A Pilot Study to Assess Dry Mouth Relief After Using an Experimental Mouth Rinse

Mobile Health to Improve Oral Chemotherapy Adherence Among Women With Breast Cancer

Oral Versus Intravenous Hydration to Prevent Contrast Induced Nephropathy

Oral Tyramine Pressor Response Study of CX157 Tablets in Healthy Male Volunteers

Mobile Weight Loss Intervention for Adolescent and Young Adult Cancer Survivors

An Open-Label Trial to Assess the Comparative Bioavailability of TV-44749 to Oral Olanzapine in Participants With Schizophrenia

MS-275 and GM-CSF in Treating Patients With Myelodysplastic Syndrome and/or Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphocytic Leukemia

Switching to Potential Reduced Exposure Products in Adult Smokers

Effect of Esomeprazole on the Pharmacokinetics of Oral Treprostinil

Sustained Release Oral Formulation For Treatment Of Parkinsons Disease

The Impact of Heavy Alcohol Use on Saliva and Oral Health

Etanercept Therapy for Sjogren's Syndrome

A Phase I Study of Oral Topotecan as a Radiosensitizing Agent in Patients With Rectal Carcinoma

TD-1473 Absorption, Distribution, Metabolism and Excretion (ADME) Study in Healthy Male Subjects